MX2022007581A - Una composicion farmaceutica de pirazol. - Google Patents

Una composicion farmaceutica de pirazol.

Info

Publication number
MX2022007581A
MX2022007581A MX2022007581A MX2022007581A MX2022007581A MX 2022007581 A MX2022007581 A MX 2022007581A MX 2022007581 A MX2022007581 A MX 2022007581A MX 2022007581 A MX2022007581 A MX 2022007581A MX 2022007581 A MX2022007581 A MX 2022007581A
Authority
MX
Mexico
Prior art keywords
pharmaceutical composition
pyrazole
surfactant
same
atopic dermatitis
Prior art date
Application number
MX2022007581A
Other languages
English (en)
Inventor
Kulczar Christopher D
Brown Chad D
Chen - Chao Wang
Fung Michelle H
Original Assignee
Intervet Int Bv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Intervet Int Bv filed Critical Intervet Int Bv
Publication of MX2022007581A publication Critical patent/MX2022007581A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/4155—1,2-Diazoles non condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2095—Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Dermatology (AREA)
  • Inorganic Chemistry (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Se describe una composición farmacéutica de un compuesto de pirazol y un tensoactivo, y un método para usar la misma para el tratamiento de dermatitis atópica.
MX2022007581A 2019-12-20 2020-12-18 Una composicion farmaceutica de pirazol. MX2022007581A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962951185P 2019-12-20 2019-12-20
PCT/EP2020/086944 WO2021123108A1 (en) 2019-12-20 2020-12-18 A pyrazole pharmaceutical composition

Publications (1)

Publication Number Publication Date
MX2022007581A true MX2022007581A (es) 2022-07-19

Family

ID=74184584

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2022007581A MX2022007581A (es) 2019-12-20 2020-12-18 Una composicion farmaceutica de pirazol.

Country Status (15)

Country Link
US (1) US20230070369A1 (es)
EP (2) EP4282475A3 (es)
JP (1) JP2023506921A (es)
KR (1) KR20220119024A (es)
CN (1) CN114845702B (es)
AU (1) AU2020409588A1 (es)
BR (1) BR112022011786A2 (es)
CA (1) CA3163925A1 (es)
DK (1) DK4076404T3 (es)
ES (1) ES2967892T3 (es)
FI (1) FI4076404T3 (es)
MX (1) MX2022007581A (es)
PL (1) PL4076404T3 (es)
PT (1) PT4076404T (es)
WO (1) WO2021123108A1 (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023118555A1 (en) * 2021-12-24 2023-06-29 Intervet International B.V. Use of aminopyrazole compounds

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2264718C (en) * 1996-09-01 2006-05-30 Pharmos Corporation Solid coprecipitates for enhanced bioavailability of lipophilic substances
JP2008514714A (ja) * 2004-09-30 2008-05-08 イーストマン ケミカル カンパニー 有意な流出阻害を示さない、親油性薬物を可溶化するビタミンｅｔｐｇｓ分子を含む医薬製剤及びこのような医薬製剤の使用
CA2816957A1 (en) * 2010-11-07 2012-05-10 Targegen, Inc. Compositions and methods for treating myelofibrosis
AU2011336478A1 (en) * 2010-12-03 2013-06-06 Novartis Ag Pharmaceutical compositions
US9248193B2 (en) * 2011-03-18 2016-02-02 Abbvie Inc. Formulations of phenyl uracil compounds
US9328099B2 (en) 2011-09-22 2016-05-03 Merck Sharp & Dohme Corp. Cyanomethylpyrazole carboxamides as janus kinase inhibitors
US20150141351A1 (en) * 2013-11-18 2015-05-21 AbbVie Deutschland GmbH & Co. KG Solid Pharmaceutical Compositions
WO2018108969A1 (en) 2016-12-14 2018-06-21 Intervet International B.V. Aminopyrazoles as selective janus kinase inhibitors
CN111465412A (zh) * 2017-12-21 2020-07-28 英特维特国际股份有限公司 Nk-1拮抗剂的口服药物组合物

Also Published As

Publication number Publication date
EP4076404A1 (en) 2022-10-26
JP2023506921A (ja) 2023-02-20
EP4076404B1 (en) 2023-11-15
EP4282475A3 (en) 2024-02-28
CN114845702B (zh) 2024-03-15
KR20220119024A (ko) 2022-08-26
AU2020409588A1 (en) 2022-06-09
US20230070369A1 (en) 2023-03-09
CA3163925A1 (en) 2021-06-24
FI4076404T3 (fi) 2024-01-31
ES2967892T3 (es) 2024-05-06
PT4076404T (pt) 2024-01-12
EP4282475A2 (en) 2023-11-29
DK4076404T3 (da) 2024-01-22
PL4076404T3 (pl) 2024-02-19
WO2021123108A1 (en) 2021-06-24
CN114845702A (zh) 2022-08-02
BR112022011786A2 (pt) 2022-08-30

Similar Documents

Publication Publication Date Title
WO2019027267A3 (ko) Atp 포스포리보실 전이효소 변이체 및 이를 이용한 l-히스티딘 생산방법
MX2020007799A (es) Inhibidores de cinasa no derrepresible de control de aminoacido general 2 (gcn2) y sus usos.
SG10201907699YA (en) Substituted pyrazole compounds as serine protease inhibitors
WO2019099682A9 (en) Compositions and methods for treating immune disorders using immune modulating lactococcus bacteria strains
EP4282479A3 (en) Use of pridopidine to treat depression or anxiety
MX2021016034A (es) Composiciones y métodos de tratamiento de una afección mediada por th2 usando prevotella.
MX2019015744A (es) Composiciones farmaceuticas.
MX2019002672A (es) Usos de antagonistas de il-13 para el tratamiento de dermatitis atopica.
MX2021010460A (es) Metodo de tratamiento con tradipitant.
MX2023010206A (es) Inhibidores de calicreina plasmatica y uso de los mismos para prevenir el ataque del angioedema hereditario.
MX2020005641A (es) Recubrimiento anti-microbiano y metodo para formar el mismo.
EP3743074A4 (en) COMPOSITION AND METHOD FOR REDUCING THROMBOCYTOPENIA BY THE ADMINISTRATION OF PLINABULINE
MX2020000367A (es) Inhibidores de rad51.
PH12018502233A1 (en) ErbB INHIBITORS AND USES THEREOF
WO2017200873A8 (en) COMPOSITIONS AND METHODS FOR TREATING ACNE
AU2018282018A1 (en) Compositions and methods for reducing flatulence
AU2017247004A1 (en) Method of treating atherosclerosis
MY187381A (en) Methods, compositions and uses relating thereto
MX2018000291A (es) Metodos para tratar la colitis.
EP4234552A3 (en) 3-phosphoglycerate dehydrogenase inhibitors and uses thereof
WO2019045360A3 (ko) 액상 플라즈마를 이용한 켈로이드의 예방 또는 치료 방법
MX2022000743A (es) Tratamiento mejorado utilizando eyp001.
PH12020550834A1 (en) Fermented soybean composition and method for producing fermented soybean composition
GB2547812A (en) Proppant composition and method
MX2022007581A (es) Una composicion farmaceutica de pirazol.